Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK6 | Q00534 | 20/20 | 0.75 |
| ▸ | CDK4 | P11802 | 19/20 | 0.75 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.75 |
| ▸ | CDK2 | P24941 | 5/20 | 0.75 |
| ▸ | CSF1R | P07333 | 3/20 | 0.75 |
| ▸ | CCNK | O75909 | 1/20 | 0.75 |
| ▸ | CDK7 | P50613 | 1/20 | 0.75 |
| ▸ | CDK9 | P50750 | 1/20 | 0.75 |
| ▸ | CCNH | P51946 | 1/20 | 0.75 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.75 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.63 |
| ▸ | CCND3 | P30281 | 3/20 | 0.57 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | CCND1 | P24385 | 1/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22983965 | 1.00 | CDK6 (0.75) | CDK6CDK4CCNA2CDK2CSF1R | |
| SCHEMBL21267755 | 0.89 | CDK4 (0.75) | CDK6CDK4CCNA2CDK2CSF1R | |
| SCHEMBL24632783 | 0.86 | CDK6 (0.65) | CDK6CDK4CCNA2CDK2CSF1R | |
| SCHEMBL24632519 | 0.86 | CDK6 (0.65) | CDK6CDK4CCNA2CDK2CSF1R | |
| Inixaciclib SCHEMBL29780787 | 0.85 | CDK4 (1.00) | CDK6CDK4CCNA2CDK2CSF1R | |
| Inixaciclib SCHEMBL21245766 | 0.85 | CDK4 (1.00) | CDK6CDK4CCNA2CDK2CSF1R | |
| SCHEMBL21267760 | 0.85 | CDK4 (0.75) | CDK6CDK4CCNA2CDK2CSF1R | |
| SCHEMBL21267494 | 0.85 | CDK4 (0.75) | CDK6CDK4CCNA2CDK2CSF1R | |
| Inixaciclib SCHEMBL21245586 | 0.85 | CDK4 (0.98) | CDK6CDK4CCNA2CDK2CSF1R | |
| Inixaciclib SCHEMBL30063971 | 0.85 | CDK4 (0.98) | CDK6CDK4CCNA2CDK2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347187-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO OPERATING COMPANY LLC | 2022-11-03 | — | — | US | disclosed |
| EP-4013743-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347187-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CDK6 2/4885CDK4 1/4885CCNA2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.